Medical Devices APAC

APAC Digital Diabetes Management Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Digital Diabetes Management Market Industry Trends and Forecast to 2034: Segmented by (Product, Type, End-user, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Buy the full report

Report snapshot

APAC Digital Diabetes Management Market Analysis at a glance
Market size, 2025Researched figures come with the full report
Forecast, 2034Researched figures come with the full report
Growth (CAGR), 2025–2034Researched figures come with the full report
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, type and end-user (see all)
Key playersMedtronic, Abbott Laboratories, Dexcom, Inc., Roche Diabetes Care, Ascensia Diabetes Care and 5 more (see all)
FormatsPDF, PPTX, XLSX

The APAC Digital Diabetes Management Market Analysis Executive Summary

Digital Diabetes Management refers to the use of technology, including mobile applications, wearable devices, and telehealth services, to assist individuals in managing their diabetes effectively. This approach enables real-time monitoring of blood glucose levels, medication adherence, and lifestyle choices, providing personalized feedback and support. The global scenario for digital diabetes management is rapidly evolving, with a significant increase in the adoption of these technologies. According to a report by the American Diabetes Association, nearly 60% of adults with diabetes are using digital tools to manage their condition, reflecting a growing trend towards integrating technology into diabetes care.

The adoption of digital diabetes management solutions has been accelerated by the COVID-19 pandemic, which prompted many healthcare providers to establish virtual clinics. These clinics leverage digital data collected from devices to offer tailored treatment recommendations. Furthermore, advancements in artificial intelligence (AI) and data analytics are enhancing the effectiveness of these tools, allowing for more precise adjustments to treatment plans. As healthcare continues to embrace digital transformation, the shift towards digital solutions not only empowers patients but also supports healthcare providers in delivering more efficient and effective care.

APAC Digital Diabetes Management Market Dynamics

Market Growth Drivers

One of the most significant drivers is the perceived benefit of these technologies in improving diabetes control and patient outcomes. Research indicates that patients who recognize the advantages of using mobile health apps and digital tools, such as enhanced self-monitoring and personalized feedback, are more likely to adopt these solutions. Additionally, recommendations from healthcare professionals play a crucial role; when clinicians endorse the use of DDM tools, patients are more inclined to engage with them. A study found that younger, tech-savvy individuals are particularly receptive to adopting these technologies, further indicating that familiarity with digital tools enhances acceptance

Opportunity

Companies like Glyconics are developing needle-free diabetes testing using infrared technology, which could revolutionize blood sugar monitoring by providing quick and painless assessments. Additionally, Fractyl Health is innovating with its Revita procedure, which aims to improve blood glucose control through endoscopic techniques, showcasing a shift towards more holistic and minimally invasive treatments

Market Restraints

The adoption of Digital Diabetes Management faces notable challenges. Resistance to change among patients, particularly older adults or those with lower technological literacy can hinder uptake. A systematic review highlighted that individuals with less education and older age groups are less likely to utilize digital tools for diabetes management. Furthermore, concerns regarding data privacy and security can create apprehension among users, deterring them from engaging with DDM solutions. The lack of consistent recommendations from healthcare providers also contributes to this hesitancy

Competitive Landscape for Digital Diabetes Management Market in APAC

Key Players

Recent Developments

Jun 2024, DexCom, Inc. a global leader in real-time continuous glucose monitoring, has expanded its Automated Insulin Delivery (AID) partnership to the Netherlands. People with Type 1 diabetes in the Netherlands can now use the new tubeless Omnipod® 5 Hybrid Closed Loop (HCL) system, integrated with the Dexcom G6 CGM, for easier diabetes management

Jan 2024, Medtronic plc secured CE Mark approval for its MiniMed™ 780G system featuring the new Simplera Sync™ continuous glucose monitor (CGM). This advanced CGM requires no fingersticks or overtape, offers a simplified two-step insertion process, and is half the size of previous sensors

Healthcare Policies and Regulatory Landscape for Digital Diabetes Management Market in APAC

Digital Diabetes Management in APAC: rules and payment

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20].

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

In the U.S., the Centers for Medicare & Medicaid Services (CMS) has expanded telehealth coverage, including remote diabetes monitoring, enabling healthcare providers to deliver care remotely and track patient data through digital tools. The FDA has also granted emergency use authorization for certain at-home diabetes devices, boosting Digital Diabetes Management (DDM) adoption during the pandemic. The reimbursement landscape is evolving, with more insurers covering continuous glucose monitors (CGMs) and other DDM tools, making them accessible to patients.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Digital Diabetes Management right now, from free public sources.

Clinical trials

124 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

Diabetes (adults), % of adults (WHO)
CountryValueYear
Afghanistan25.32022
Australia8.12022
Bangladesh17.92022
China11.22022
India22.62022
Indonesia12.82022
Japan6.42022
Malaysia26.72022
Myanmar13.82022
Nepal15.82022
New Zealand9.02022
Pakistan30.92022
Philippines13.22022
Singapore13.12022
Thailand12.32022
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Digital Diabetes Management in context

Free data on this topic

Quick answers

Frequently asked questions

What segments does the Digital Diabetes Management market report cover?
The report splits the market by product (Devices, Digital Diabetes Apps), type (Wearable Devices, Handheld Devices) and end-user (Hospitals & Specialty Diabetes Clinics, Homecare Settings, Academic & Research Institutes, Self/Home Users).
Who are the key players in the Digital Diabetes Management market?
Key players include Medtronic, Abbott Laboratories, Dexcom, Inc., Roche Diabetes Care, Ascensia Diabetes Care and Tandem Diabetes Care, among 10 companies the report profiles.
What is driving the Digital Diabetes Management market?
One of the most significant drivers is the perceived benefit of these technologies in improving diabetes control and patient outcomes.
Back to Catalogue

Related Medical Devices reports in APAC

See all

Related on diabetes and digital health

See the topic